Application of propranolol or pharmaceutically acceptable salt thereof in preparation of medicine for inhibiting lung cancer meningometastasis
By using propranolol to block the neuroendocrine differentiation of lung cancer cells, the treatment challenge of lung cancer leptomeningeal metastasis was solved, the survival time of mice with lung cancer leptomeningeal metastasis was significantly prolonged, and effective inhibition of lung cancer leptomeningeal metastasis was achieved.
Patent Information
- Application Number
- CN202411625430.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-11-14
- Publication Date
- 2026-05-22
Smart Images

Figure CN122070912A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biomedical technology, specifically relating to the use of propranolol or its pharmaceutically acceptable salts in the preparation of drugs that inhibit meningeal metastasis in lung cancer. Background Technology
[0002] Lung cancer is a malignant disease with high incidence and mortality rates, accounting for approximately 20% of all cancer deaths. In recent years, with the development of molecular target subtyping such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and programmed death ligand 1 / Ligand 1 (PD-1 / PD-L1), precision medicine models for lung cancer have been gradually established, offering the possibility of long-term survival for patients with advanced lung cancer. Overall survival (OS) for patients with advanced lung cancer has increased from 8-10 months in the era of traditional chemotherapy to 30-40 months in the era of precision combination therapy. However, leptomeningeal metastasis (LM) remains one of the most fatal complications of advanced lung cancer, with an incidence rate of 5%-10%. Patients with leptomeningeal metastasis have an extremely poor prognosis; depending on the treatment regimen, the median survival ranges from 1-3 months to 3-11 months. Patients with lung cancer metastases to the meninges have severe clinical symptoms and poor prognosis, and there is still a lack of specific and systematic treatment options.
[0003] In recent years, the mechanisms underlying the multi-step processes of meningeal metastasis have been a hot topic in the field. A research group at Memorial Sloan Kettering Cancer Center discovered that upregulated expression of complement component 3 (C3) on metastatic tumor cells activates C3a receptors on choroid plexus epithelial cells, disrupting the blood-brain barrier and allowing plasma components, including bimodalin and other mitogens, to enter the cerebrospinal fluid (CSF) and promote tumor cell growth. Furthermore, they found that tumor cells in the CSF utilize the lipid transporter 2 / soluble carrier transporter 22A17 iron transport system to compete with macrophages for scarce iron ions in the CSF microenvironment, thereby promoting tumor cell survival and proliferation in the CSF environment. Two teams from the University of Toronto and the University of Southern California, respectively, discovered that medulloblastoma promotes meningeal metastasis through the γ-aminobutyrate transaminase (GABA) and chemokine ligand / receptor 2 pathways. A team at the Beckman Institute demonstrated that macrophage colony-stimulating factor (CSCGF) secreted by epidermal growth factor receptor 2 (EGFR2) mutation-positive breast cancer cells is closely related to the occurrence of meningeal metastasis. In animal models, blocking CSCGF secretion with inhibitors slowed the growth of EGFR2 mutation-positive tumors and prolonged survival. While this research greatly deepens our understanding of the characteristics of meningeal metastatic cells or the microenvironment, there are currently no targets that can be translated into clinical treatments, and a precise intervention strategy for meningeal metastasis is lacking.
[0004] Neuroendocrine differentiation (NED) in tumors refers to the process by which tumor cells express neuroendocrine-related genes and proteins, and simultaneously produce and release neuroendocrine substances within the tumor microenvironment. NED has been observed in many non-neuroendocrine organ tumors, such as those of the lung, gastrointestinal tract, pancreas, skin (Mekel cells), and the genitourinary system. 20% of lung cancers exhibit neuroendocrine differentiation. In recent years, the transformation of lung adenocarcinoma into small cell lung cancer or neuroendocrine differentiation has been considered a possible mechanism for drug resistance. Transdifferentiated lung cancer is often associated with rapid malignant progression and poor prognosis, but currently, no research has established a relationship between neuroendocrine differentiation and meningeal metastasis.
[0005] Recent studies on the mechanisms of tumor brain metastasis have shown that tumor cells acquiring neural cell characteristics is a key factor in adapting to the malignant environment required for colonization in the brain microenvironment. Various tumor cells can "disguise" themselves as neural cells to hijack the nervous system and promote tumor growth and metastasis. This process involves multiple mechanisms, such as receiving and responding to electrical signals from neurons, the exchange of which promotes tumor cell growth, spread, and increased invasiveness; mimicking neurons to form synaptic structures, thereby establishing direct physical connections with the nervous system, allowing tumor cells to directly receive signals from neurons, including signals that promote growth and division; and promoting tumor cell growth and survival by secreting or inducing the host tissue to produce nerve growth factors.
[0006] Studies have found that breast cancer brain metastases exhibit a GABAergic receptor phenotype similar to neurons, thereby acquiring the malignant adaptations required for colonization in the brain microenvironment. However, no research has yet elucidated the relationship between neuroendocrine differentiation in lung cancer and its leptomeningeal metastasis, nor have there been reports demonstrating that intervening in the neuroendocrine differentiation of lung cancer can inhibit leptomeningeal metastasis. Therefore, in-depth research into the molecular regulatory mechanisms of lung cancer leptomeningeal metastasis and the provision of effective interventions for leptomeningeal metastasis have significant application value for lung cancer treatment. Summary of the Invention
[0007] To address the shortcomings of existing technologies, the present invention aims to provide the application of propranolol or its pharmaceutically acceptable salts in the preparation of drugs for inhibiting lung cancer meningeal metastasis. This invention is the first to discover the application of blocking neuroendocrine differentiation in the prevention and treatment of meningeal metastasis, specifically by using propranolol to block the neuroendocrine differentiation of lung cancer cells. This weakens the survival ability of lung cancer cells in the cerebrospinal fluid environment, thereby inhibiting lung cancer meningeal metastasis. In other words, by inhibiting the neuroendocrine differentiation of lung cancer cells with propranolol, lung cancer meningeal metastasis is treated, ultimately improving or curing lung cancer.
[0008] To achieve this objective, the present invention adopts the following technical solution:
[0009] In a first aspect, the present invention provides the use of substances that block neuroendocrine differentiation in the preparation of drugs that inhibit meningeal metastasis of lung cancer cells.
[0010] Currently, no research has shown a relationship between neuroendocrine differentiation and meningeal metastasis. The study in this invention found that lung cancer cells that have undergone meningeal metastasis exhibit characteristics of neuroendocrine differentiation, and this cellular transformation may be a necessary pathway for lung cancer cells to undergo meningeal metastasis.
[0011] In a second aspect, the present invention provides the use of propranolol or a pharmaceutically acceptable salt thereof in the preparation of a medicament for inhibiting meningeal metastasis in lung cancer.
[0012] Propranolol is a non-selective beta-blocker widely used to treat various cardiovascular diseases, such as hypertension, arrhythmias, and angina. It is also used to prevent migraines, relieve anxiety symptoms, and treat certain types of tremors (such as essential tremor). Furthermore, propranolol can inhibit tumor cell proliferation, migration, invasion, and angiogenesis, and improve the tumor microenvironment. The results of this invention show that by blocking the neuroendocrine differentiation of lung cancer with propranolol, and further by blocking the neuroendocrine differentiation of lung cancer, the leptomeningeal metastasis of lung cancer can be inhibited.
[0013] This invention discloses for the first time the application of blocking neuroendocrine differentiation in the prevention and treatment of meningeal metastasis, specifically by using propranolol to block neuroendocrine differentiation in lung cancer. This weakens the survival ability of lung cancer cells in the cerebrospinal fluid environment, thereby inhibiting lung cancer meningeal metastasis. In other words, by inhibiting the neuroendocrine differentiation of lung cancer cells with propranolol, lung cancer meningeal metastasis can be treated, ultimately improving or curing lung cancer.
[0014] Preferably, the drug blocks the neuroendocrine differentiation of lung cancer cells.
[0015] Preferably, the drug inhibits the formation of neural synaptic structures.
[0016] Preferably, the drug reduces the survival ability of lung cancer cells in the cerebrospinal fluid environment.
[0017] This invention discovers a new use for an old drug, namely, the novel application of propranolol in meningeal metastasis, which inhibits lung cancer meningeal metastasis by suppressing the neuroendocrine differentiation pathway.
[0018] This invention obtains lung cancer cells (Lep cells) with high meningeal metastasis capacity using a mouse model. Transcriptome sequencing revealed upregulated expression of genes related to neuroendocrine differentiation regulation in Lep cells. Further analysis showed upregulated expression of genes such as MAP2, SOX2, ASCL2, NSE, SSTR1, and SSTR5 in Lep cells, changes in Lep cell morphology, the presence of neural synaptic structures, and upregulated secretion of neuroenolase NSE, suggesting that Lep cells undergo neuroendocrine differentiation.
[0019] In this invention, by co-culturing tumor cells with cerebrospinal fluid (CSF) to simulate tumor proliferation in the CSF microenvironment, it was found that Lep cells have a stronger survival ability in CSF. Analysis of clinical data from lung cancer patients revealed a positive correlation between high expression of neuroendocrine differentiation-related genes (MAP2, SOX2, ASCL2, NSE, SSTR1, and SSTR5) in tumor tissue and the degree of meningeal metastasis and disease progression. Treatment with propranolol blocked the neuroendocrine differentiation of lung cancer cells, reduced their survival ability in the CSF environment, inhibited tumor cell growth in a mouse model of lung cancer meningeal metastasis, and significantly prolonged the overall survival of mice with lung cancer meningeal metastasis.
[0020] Thirdly, the present invention provides the use of propranolol or a pharmaceutically acceptable salt thereof in the preparation of a neuroendocrine differentiation inhibitor for lung cancer cells.
[0021] This invention provides a drug for inhibiting meningeal metastasis in lung cancer, wherein the active ingredient of the drug comprises propranolol or a pharmaceutically acceptable salt thereof.
[0022] Preferably, the drug further includes pharmaceutically acceptable excipients.
[0023] Preferably, the excipients include any one or a combination of at least two of the following: excipients, diluents, carriers, flavoring agents, binders, fillers, disintegrants, or pH adjusters.
[0024] Fourthly, the present invention provides a method for constructing a mouse model of lung cancer leptomeningeal metastasis, the method comprising: injecting lung cancer cells with FUS gene knocked out into the left ventricle of a mouse to obtain a mouse model of lung cancer leptomeningeal metastasis.
[0025] Preferably, the step of knocking out the FUS gene includes: infecting lung cancer cells with a lentivirus containing sgRNA and Cas9 that target the FUS gene, and then screening to obtain lung cancer cells with the FUS gene knocked out.
[0026] Preferably, the nucleotide sequence targeted by the sgRNA includes those shown in SEQ ID NO:1 and SEQ ID NO:2.
[0027] SEQ ID NO: 1: FUS-sg1: TATGGCTCGACTGGCGGCTA.
[0028] SEQ ID NO:2: FUS-sg2:CGCCAGTCGAGCCATATCCC.
[0029] Fifthly, the present invention provides the application of the mouse model of lung cancer leptomeningeal metastasis described in the fourth aspect in evaluating the therapeutic effect of drugs that inhibit lung cancer leptomeningeal metastasis.
[0030] In this invention, to further investigate the molecular regulatory processes of meningeal metastasis in lung cancer cells, a human genome-wide knockout library (addgene, pooled libraries, Human CRISPR Knockout Pooled Library (GeCKO v2) (library A+B)) was used. Based on this CRISPR / Cas9 gene knockout system, lung cancer cell lines were modeled to screen for genes related to lung cancer meningeal metastasis. The screening results showed that sgRNAs targeting FUS were significantly enriched in all four lung cancer cell lines with meningeal metastasis, suggesting that FUS deletion is involved in regulating lung cancer meningeal metastasis.
[0031] In this invention, to further confirm whether FUS deficiency directly promotes meningeal metastasis, FUS was further knocked out in lung cancer cell lines using a CRISPR / Cas9 gene knockout system. FUS-deficient tumor cells exhibited enhanced blood-brain barrier (BCSFB) penetration ability. In a mouse model, FUS knockout enhanced the meningeal metastasis ability of lung cancer cells, and transplantation of FUS-deficient lung cancer cells significantly shortened the survival time of mice. In Lep cells, FUS expression levels were also significantly reduced, indicating that the absence of FUS expression promotes meningeal metastasis in lung cancer.
[0032] Based on the fact that the loss of FUS expression promotes leptomeningeal metastasis of lung cancer, this invention constructs a mouse model of lung cancer leptomeningeal metastasis. Lung cancer cells with the FUS gene knocked out are injected into the left ventricle of mice to obtain a mouse model of lung cancer leptomeningeal metastasis. The model can be used to detect or evaluate the therapeutic effect of drugs for treating lung cancer leptomeningeal metastasis.
[0033] This invention provides a biomarker for lung cancer meningeal metastasis, wherein the biomarker is neuroenolase (NSE).
[0034] In this invention, lung cancer cells with high leptomeningeal metastasis capacity were enriched, and recombinant lung cancer cells with high leptomeningeal metastasis capacity were constructed by gene editing technology. Through the study of the above-mentioned cells with high leptomeningeal metastasis capacity, transcriptome sequencing revealed that the expression of genes related to neuroendocrine differentiation regulation was upregulated in Lep cells and lung cancer cells with FUS gene knockout. The expression of genes such as MAP2, SOX2, ASCL2, NSE, SSTR1, and SSTR5 was upregulated, and the secretion of neuroenolase NSE was upregulated. Neural synaptic structures appeared in Lep cells and FUS-deficient cells, and the expression of the neurodifferentiation-related marker MAP2 was positive, suggesting the neurodifferentiation of tumor cells.
[0035] Sixthly, the present invention provides the application of a reagent for detecting the secretion level of neuroenolase NSE in the preparation of products for diagnosing lung cancer leptomeningeal metastases.
[0036] In this invention, the product diagnoses lung cancer leptomeningeal metastasis by detecting the secretion level of neuroenolase NSE.
[0037] In a seventh aspect, the present invention provides the use of neuroenolase NSE as a detection and / or therapeutic target in the preparation of products for diagnosing and / or inhibiting leptomeningeal metastasis of lung cancer.
[0038] Compared with the prior art, the present invention has the following beneficial effects:
[0039] This invention discloses for the first time the application of blocking neuroendocrine differentiation in the prevention and treatment of meningeal metastasis, and discovers that propranolol can be used as a drug to block neuroendocrine differentiation in the treatment of lung cancer meningeal metastasis. By blocking the neuroendocrine differentiation of lung cancer cells with propranolol, the survival ability of lung cancer cells in the cerebrospinal fluid environment can be weakened, thereby inhibiting lung cancer meningeal metastasis. In other words, lung cancer meningeal metastasis is treated by inhibiting the neuroendocrine differentiation of lung cancer cells with propranolol, ultimately improving or treating lung cancer.
[0040] This invention obtained lung cancer cells (Lep cells) with high leptomeningeal metastasis capacity using a mouse model. It was also found that lung cancer cells lacking FUS gene expression promote leptomeningeal metastasis of lung cancer. Transcriptome sequencing revealed upregulated expression of genes related to neuroendocrine differentiation regulation in Lep cells. Further analysis showed upregulated expression of genes such as MAP2, SOX2, ASCL2, NSE, SSTR1, and SSTR5 in Lep cells. Lep cell morphology changed, exhibiting neural synaptic structures, and the secretion of neuroenolase NSE was upregulated, suggesting that Lep cells undergo neuroendocrine differentiation.
[0041] This invention simulates tumor proliferation in the cerebrospinal fluid microenvironment by co-culturing tumor cells with cerebrospinal fluid, revealing that Lep cells exhibit stronger survival capabilities in cerebrospinal fluid. Analysis of clinical data from lung cancer patients showed a positive correlation between high expression of neuroendocrine differentiation-related genes (MAP2, SOX2, ASCL2, NSE, SSTR1, and SSTR5) in tumor tissue and the degree of meningeal metastasis and disease progression. Propranolol treatment blocked neuroendocrine differentiation of lung cancer cells, reduced their survival ability in the cerebrospinal fluid environment, inhibited tumor cell growth in a mouse model of lung cancer meningeal metastasis, and significantly prolonged the overall survival of mice with lung cancer meningeal metastasis.
[0042] In summary, this invention reveals that neuroendocrine differentiation is a key regulatory factor in lung cancer meningeal metastasis, and that inhibiting lung cancer meningeal metastasis by blocking neuroendocrine differentiation in lung cancer with propranolol has potential development prospects. Attached Figure Description
[0043] Figure 1 To construct a mouse model of lung cancer with dural metastasis.
[0044] Figure 2 The results of screening key regulatory genes for lung cancer dural metastasis are shown in the figure.
[0045] Figure 3 This provides experimental validation of the results showing that FUS deficiency promotes leptomeningeal metastasis in lung cancer.
[0046] Figure 4 These are molecular characteristics of lung cancer cells that have metastasized to the meninges.
[0047] Figure 5 The results show the staining and co-culture of Lep cells and FUS-deficient cells.
[0048] Figure 6 The results of experiments showing that propranolol inhibits meningeal metastasis.
[0049] Figure 7 This is a statistical analysis of the survival rate of tumor-bearing mice. Detailed Implementation
[0050] The technical solution of the present invention will be further illustrated below through specific embodiments. Those skilled in the art should understand that the embodiments described are merely illustrative of the present invention and should not be construed as limiting the invention.
[0051] Where specific techniques or conditions are not specified in the examples, they shall be performed in accordance with the techniques or conditions described in the literature in this field, or in accordance with the product instructions. Reagents or instruments whose manufacturers are not specified are all conventional products that can be purchased through legitimate channels.
[0052] The experimental materials and instruments used in the following examples are shown below:
[0053] In this invention, the A549 and PC9 cell lines were purchased from the American College of Cell Bank (ATCC). For ease of observation, the cell lines were genetically engineered to introduce luciferase and green fluorescent protein (GFP) genes for in vivo observation. The culture medium used was RPMI-1640 complete medium (containing 10% fetal bovine serum and 1% penicillin-streptomycin solution). The incubator temperature was set at 37°C, and the carbon dioxide concentration was maintained at 5%. Cells were passaged and the medium was changed after reaching 80% confluence.
[0054] The animal experiments in this invention were conducted at the Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences (GIBH). The animals used in the experiments were self-developed specific pathogen-free (SPF) NOD-SCID / IL2gr- / -(NSI) mice (Patent No.: ZL201310229629.9). The management and use of all experimental animals were reviewed and approved by the GIBH Laboratory Animal Ethics Management Committee, following the international AAALAC standards, and were raised and bred at the GIBH SPF Laboratory Animal Center (Laboratory Animal Facility License Number: SYXK (Guangdong) 2020-0063).
[0055] Example 1
[0056] Construction of a mouse model of meningeal metastasis
[0057] In this example, an immunodeficient mouse NOD-SCID / IL2gr- / -(NSI) was used to establish a humanized animal model of lung cancer meningeal metastasis. Tumor cells (Par) were transplanted into the cisterna magna of the mice. After the mice developed symptoms, tumor cells were isolated from the cerebrospinal fluid and transplanted into the cisterna magna of the mice again. After repeating the transplantation 3 times, the isolated tumor cells were transplanted into the mice by left ventricular injection, and the tumor cells (Lep) that spontaneously metastasized to the cerebrospinal fluid were collected. The ability of Lep cells to penetrate the blood-brain barrier was evaluated by Transwell experiment, and the meningeal metastasis potential of Lep cells in the mice was evaluated by left ventricular injection.[[ID=,10]]
[0058] 1. Experimental procedures
[0059] (1) The process of enriching lung cancer cells with high meningeal metastasis ability is as follows: Lung cancer cells were inoculated into the cisterna magna of the mice. When the mice showed obvious central nervous system tumors, significant weight loss, unsteady gait, and arched back, etc., the mice were sacrificed and the lung cancer cells in the cerebrospinal fluid were collected. Then, the collected cancer cells were inoculated into another batch of mice. After raising for a period of time, the lung cancer cells in the cerebrospinal fluid were collected again. The intracerebroventricular injection was repeated three times. Finally, the obtained cells were injected into the left ventricle of the mice. After raising for a period of time, the fluorescence signal in the brain was monitored by fluorescence in vivo imaging. After the above-mentioned signs of sacrifice appeared, the mice were sacrificed and the lung cancer cells in the cerebrospinal fluid were collected and named "Lep" cells.
[0060] (2) The procedure for intraventricular injection is as follows: Anesthetize the mouse and fix it on the puncture board with its limbs extended, abdomen facing down, and back facing up. When exposing the puncture site, use ophthalmic scissors to cut the skin of the head about 1-2 cm along the midline of both ears. Then, using hemostatic forceps, gradually separate the subcutaneous fascia and muscle from the foramen magnum until the white aponeurosis located under the muscle (the connection between the foramen magnum and the atlas) is visible. Stop the separation and place a 15 mL centrifuge tube under the mouse's neck to fully expose the back of the neck. When performing the puncture injection, remove the centrifuge tube containing the cell suspension to be injected from the ice box, gently tap the bottom of the centrifuge tube to mix the cell suspension, and use a 50 μL microsyringe to draw 5 μL of the cell suspension (approximately 5 × 10⁻⁶ cells). 4 With your left hand, use forceps to spread the muscle (use hemostatic forceps for fixation if necessary). With your right hand, hold a microsyringe and insert the needle at an angle of approximately 60-70° to the white fascia, feeling for a slight loss of pressure. Insert the needle about 1.5 mm, maintaining this depth, and then slowly inject the cell suspension at a rate of 5 μL / min. During the injection, monitor the mouse's heartbeat and vital signs to ensure no air bubbles are introduced. After the injection, slowly withdraw the needle, reposition the muscle, and observe the mouse's survival for 30 seconds. Once normal, intermittently suture the skin behind the mouse's head and mark the area.
[0061] (3) The ventricular injection procedure is as follows: Anesthetize the mouse and fix it on the puncture board in a position with limbs extended and chest facing upwards. When exposing the puncture site, observe the area where the mouse's heartbeat is most pronounced. Starting from the xiphoid process, dissect the mouse's chest skin step by step until reaching the clavicular plane. After cutting the skin, use the index and middle fingers of your left hand to fix the skin on both sides of the mouse's chest, fully exposing the thoracic cavity. Locate the area where the pulsation is most pronounced, approximately 2 to 5 millimeters to the left of the midpoint between the xiphoid process and the clavicular end of the sternum. Disinfect twice with alcohol swabs and wipe once with sterile gauze. Remove the cell suspension to be injected from the icebox, gently tap the bottom of the centrifuge tube to thoroughly mix the cell suspension, and draw 100 μL of the cell suspension using a 1 mL syringe. Hold the skin on both sides of the mouse's chest with your left hand to fully expose the thoracic cavity. Holding the syringe in the right hand, insert the needle at an angle of approximately 60 to 70 degrees, below the upper edge of the rib below the intercostal space where the heartbeat is most pronounced. When the needle is about one-third of the way in, aspirate and maintain negative pressure, slowly inserting it deeper until bright red blood flows into the syringe, indicating that the needle has entered the left ventricle. Maintaining the same depth, slowly inject the cell suspension at a rate of 50 μL / min. Observe the mouse's heartbeat and respiratory rate. If bright red blood is still aspirated during injection, continue injection; if no aspiration occurs or resistance is felt, consider withdrawing the needle for inspection. After injection, slowly withdraw the needle and observe the mouse's vital signs for 30 seconds. After confirming normal function, suture the external skin of the chest cavity and mark the area. Monitor the tumor burden in the mouse's brain using in vivo imaging (BLI).
[0062] (4) Mouse euthanasia: When mice exhibited significant neurological symptoms and could not continue to survive, they were euthanized by carbon dioxide asphyxiation. The mouse skull was opened in a sterile environment, and the base of the skull and the surface of the brain were rinsed with 2 mL of sterile PBS. The collected cerebrospinal fluid was centrifuged at 500 g for 5 minutes, and the red blood cells were lysed. The remaining cells were resuspended in RPMI 1640 medium containing 10% fetal bovine serum (FBS) for culture.
[0063] (5) Transwell assay (cell migration assay): Dilute Matrigel with PBS to a 20% concentration mixture, drop it onto the upper chamber membrane of an 8μm pore size Transwell, and incubate overnight in an incubator to solidify. After the Matrigel has solidified, collect approximately 2 × 10⁶ cells. 5 Brain vascular endothelial cells were resuspended in complete culture medium, seeded into the upper chamber of a Transwell culture, and cultured for 24 hours to allow the endothelial cells to form a monolayer cell membrane to mimic the blood-cerebrospinal fluid barrier (BCSFB). 1×10⁶ cells were then used. 5 Tumor cells were resuspended in 1% serum-concentrated complete culture medium and seeded into the upper chamber of a Transwell incubator. Simultaneously, 300 μL of cerebrospinal fluid was added to the lower chamber, and the cells were cultured in a cell culture incubator for 48 hours. Tumor cells that migrated to the lower chamber were collected, and the cell count was determined.
[0064] 2. Experimental Results
[0065] This embodiment established a humanized lung cancer leptomeningeal metastasis animal model using immunodeficient mice (NOD-SCID / IL2gr- / - (NSI)). Results showed that Lep cells possessed stronger leptomeningeal metastasis ability, and the survival time of mice transplanted with Lep cells was significantly reduced. Transwell assays showed that Lep cells had stronger BCSFB penetration ability. Therefore, the tumor cells (Lep) obtained through the above method have highly efficient leptomeningeal metastasis ability. Figure 1 ).
[0066] Figure 1 To construct a mouse model of lung cancer with dural metastasis.
[0067] Figure 1 Diagram A: The steps for constructing a mouse model of lung cancer leptospirosis metastasis are illustrated as follows: Lung cancer cells are injected into the cerebrospinal fluid (CSF) of mice via intraventricular injection. Tumor cells in the CSF are collected, expanded in vitro, and then transplanted back into the CSF. This transplantation is repeated three times. The enriched tumor cells are then transplanted into mice via left ventricular injection, and tumor cells that spontaneously metastasize to the CSF are collected. Par: Tumor cells before enrichment; Int: Tumor cells during enrichment; Lep: Tumor cells with high metastatic potential after enrichment.
[0068] Figure 1In the middle B: A549-Par / Lep cells were transplanted into mice through the left ventricle, and tumor progression in mice was detected by in vivo imaging. The survival time and the proportion of meningeal metastasis in mice were statistically analyzed; LM: meningeal metastasis; Non-LM: non-meningeal metastasis.
[0069] Figure 1 C: Mouse brain tissue pathological sections and keratin immunohistochemical analysis show tumor lesions in the meningeal structure. Scale bar: whole brain map 2000μm, screenshot 200μm.
[0070] Figure 1 In the middle D: PC9-Par / Lep cells were transplanted into mice through the left ventricle, and tumor progression in the mice was detected by in vivo imaging, and the survival time of the mice was recorded.
[0071] Figure 1 E: Mouse brain tissue pathological sections and keratin immunohistochemical analysis show tumor lesions in the meningeal structure. Scale bar: whole brain map 2000μm, screenshot 200μm.
[0072] Figure 1 Schematic diagram of Transwell experiment: Tumor cells are placed in the upper chamber, with matrigel and endothelial cells in the middle, and cerebrospinal fluid is placed in the lower chamber.
[0073] Figure 1 The Transwell assay results showed that Lep cells had a stronger BCSFB penetration ability than Par cells.
[0074] Example 2
[0075] CRISPR-Cas9 genome-wide knockout library screening for genes regulating meningeal metastasis.
[0076] 1. This embodiment uses human whole-genome knockout libraries (addgene, pooled libraries, HumanCRISPR Knockout Pooled Library (GeCKO v2) (library A+B)). The screening process is as follows:
[0077] (1) Lentiviral sgRNA library assembly
[0078] Cell preparation: Seed 293T cells in a 10 cm culture dish and allow them to grow to 70% to 80% confluence. Once confluence is achieved, replace the medium with complete medium containing 1% DMEM and incubate for 2 hours.
[0079] Transfection preparation: Add the helper plasmid and GeCKO v2 library plasmid to a 15 mL centrifuge tube in the specified ratio and mix gently. In another 15 mL centrifuge tube, add the amount of polyetherimide (PEI) by volume. Combine the liquids in the two tubes, gently pipette to mix, and incubate at room temperature for 20 to 30 minutes.
[0080] Transfection procedure: Add the mixture to 293T cells that have had their culture medium changed. Allow the cells to transfect for 6 to 8 hours, then change the culture medium again. Over the next 72 hours, collect the virus released from the lentiviral library's culture medium daily.
[0081] (2) Determination of lentivirus infection efficiency
[0082] Cell culture: When PC9 and A549 cells reached 80% confluence, they were counted and seeded into 10 cm culture dishes. The initial cell number was set at 3 × 10⁶ cells / year. 5 Add 10 mL of 1% DMEM complete culture medium.
[0083] Viral infection: 1 μL of polybrene was added to the culture medium, and 6 wells were set up for the experimental group and 6 wells for the control group without treatment. After four days of cell culture, 2 μg / mL of puromycin was added for selection. The control group was not treated.
[0084] Cell counting: Observe and record cell survival after adding puromycin. If cells in the 0 μL virus group completely died, perform a live cell count. Define "live cell count" as the number of cells surviving on the plate with added puromycin, and the number of cells in the control group as "control cell count".
[0085] Calculate infection efficiency and titer: Calculate the viral activity titer for each viral dose group using the following formula: Titer (IFU / mL) = (Number of viable cells × Number of starting cells) / (Number of control cells × Virus volume). Finally, calculate the average value to obtain the final titer.
[0086] Calculate the infection efficiency: Infection efficiency = number of cells in the drug-treated dish / number of cells in the untreated dish. Select a virus volume with an infection efficiency of 0.1 for virus transfection of the library.
[0087] (3) Lentiviral library transfection
[0088] Cell preparation: When A549GL and PC9GL cells reach 70% confluence, discard the culture medium and wash the cells twice with phosphate-buffered saline (PBS) to remove residual culture medium and cytokines.
[0089] Viral transfection: Based on the pre-calculated infection efficiency (=0.1), accurately measure an appropriate amount of viral solution containing the lentiviral library. Add polybrene (8 μg / mL) to the viral solution to improve transfection efficiency. Add the viral solution to the cells, mix gently, and continue culturing the cells for 2 days.
[0090] Screening: After 2 days of culture, the medium containing lentivirus was removed and replaced with fresh medium, with 2 μg / mL puromycin added for screening. Cells were cultured for another 3 days to screen for cells successfully infected and with the target gene knocked out. After screening, cells were harvested to obtain a CRISPR / Cas9 whole-genome knockout cell bank. Each cell should have exactly one gene knocked out.
[0091] (4) Whole-genome knockout cell genome library construction and sequencing
[0092] Sample preparation: 10% of the cells were taken from the CRISPR / Cas9 whole genome knockout cell pool for genome extraction.
[0093] PCR amplification: Because the sgRNA coverage is greater than 400×, the template amount needs to reach 200μg. Amplification was performed in 10 separate PCR systems.
[0094] The first PCR system was constructed as shown in Table 1. The first PCR cycle number was 35, and the PCR products were collected as templates for the second round of PCR.
[0095] Table 1
[0096] Components Volume / mass KOD polymerase 50μL gDNA 20μg <![CDATA[1 st PCR forward primers 3μL <![CDATA[1 st PCR reverse primers 3μL Double distilled water Add to 100μL
[0097] 1 st PCR forward primer: SEQ ID NO:3:
[0098] AATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCG.
[0099] 1 st PCR reverse primer: SEQ ID NO:4:
[0100] CTTTAGTTTGTATGTCTGTTGCTATTATGTCTACTATTCTTTCC.
[0101] Second round of PCR amplification: A second round of PCR amplification was performed based on the first PCR product to introduce barcodes for subsequent sequencing. The number of cycles was 35. The construction of the second round of PCR system is shown in Table 2.
[0102] Table 2
[0103] Components Volume / mass KOD polymerase 25μL Template: Product of the first PCR reaction 10μL Primers NGS-Lib-Fwd(1-10) 1.5μL Primer NGS-Lib-KO-Rev (containing index sequence) 1.5μL Double distilled water Add to 100μL
[0104] A second PCR was performed using front primers of varying lengths (NGS-Lib-Fwd, at least 7) and end primers containing the sequencing index (NGS-Lib-KO-Rev, to distinguish each sample). The forward and reverse primer sequences used were derived from Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening (PMID: 28333914).
[0105] The obtained PCR products were subjected to 1% agarose gel electrophoresis, and bands of 250 to 280 bp in size were cut and recovered to ensure that fragments that meet the sequencing requirements were obtained, thus completing the preparation for high-throughput sequencing library construction.
[0106] (5) In vivo screening experiment of animal models of meningeal transfer
[0107] Animal model establishment: Prepare experimental group cells according to the above-described method for constructing meningeal animal models, and ensure that the cells are properly treated for transplantation.
[0108] Cell transplantation: Experimental cells were injected into mice via left ventricular transplantation. Accurate positioning and rapid execution are crucial to minimize stress and impact on the mice. Cell viability and distribution were monitored in real-time using fluorescence in vivo imaging. Mice were observed promptly after transplantation.
[0109] Dissection and Sample Collection: Mice were dissected and brain samples were collected upon reaching death. Cerebrospinal fluid (CSF) was collected from the brain and flushed to remove residual cells. The obtained CSF samples were seeded into 12-well plates and cultured for 2 days to encourage cell adhesion and growth. After 2 days, the culture medium was changed to ensure the removal of dead and non-adherent cells. Cells were photographed to observe cell adhesion. Cell digestion was performed, followed by flow cytometry analysis to detect the proportion of green fluorescent protein (GFP) positive cells. The number of GFP-positive cells was recorded to assess cell survival and metastasis in the CSF.
[0110] Tumor cell sequencing and analysis: Following the library preparation procedure described above, tumor cells from the screened cerebrospinal fluid were used to construct a library and undergo gene sequencing to obtain high-throughput sequencing data. The sequencing results were compared with the gene information of the control group during high-throughput sequencing library construction to identify differentially expressed genes. Bioinformatics tools were used to perform enrichment analysis on the screened genes to assess their biological significance and potential functional pathways, and to identify possible pathogenic genes or metastasis-related biomarkers.
[0111] 2. Experimental Results
[0112] To further investigate the molecular regulation of meningeal metastasis in lung cancer cells, this study employed a human genome-wide knockout library (addgene, pooled libraries, Human CRISPR Knockout Pooled Library (GeCKOv2) (library A+B)) and modeled lung cancer cell lines based on this CRISPR / Cas9 gene knockout system, aiming to screen for genes associated with lung cancer meningeal metastasis. In vivo screening for meningeal metastasis was performed on lung cancer cells by introducing the genome-wide knockout library. Tumor cells were injected intravenously, and meningeal metastasis cell lines were isolated from cerebrospinal fluid. Results showed that sgRNAs targeting FUS were significantly enriched in all four lung cancer cell lines with meningeal metastasis, suggesting that FUS deletion is involved in regulating lung cancer meningeal metastasis. Figure 2 ). Figure 2 The results of screening key regulatory genes for lung cancer dural metastasis are shown in the figure.
[0113] Figure 2 A: Schematic diagram of the in vivo screening process for CRISPR-Cas9 targeted whole-genome knockout libraries: The sgRNA library is introduced into tumor cells via lentiviral infection, ensuring that each cell contains one sgRNA, with an sgRNA coverage of approximately 500 cells / sgRNA. The tumor cells are then transplanted into immunodeficient mice via left ventricular injection. Tumor cells that spontaneously migrate to the cerebrospinal fluid are collected, and high-throughput sequencing is performed to read the sgRNA enrichment information.
[0114] Figure 2 Sequencing analysis of mouse cerebrospinal fluid cells after CRISPR-Cas9 screening showed that FUS knockdown was detected in all four cell lines after meningeal transfer.
[0115] Figure 2 C: The Gini coefficient shows the uniformity of sgRNA distribution in tumor cells. The larger the Gini coefficient, the less uniform the sgRNA distribution. Moreover, the number of sgRNA types in tumor cells decreases after screening, indicating that sgRNA is enriched in tumor cells after in vivo screening.
[0116] Figure 2 D: The proportion of tumor cells imported into the screening library that metastasize to the meninges in mice increases.
[0117] Figure 2 E: Screening results of 4 different cell lines. The figure shows the top 10 enriched genes, and FUS ranked very high in all 4 cell lines.
[0118] Example 3
[0119] 1. Gene knockout experiments verify that FUS deletion promotes leptomeningeal metastasis in lung cancer.
[0120] sgRNA sequences targeting FUS were designed using the CRISPick sgRNA designer (https: / / portals.broadinstitute.org / gppx / crispick / public) and the CCTop-CRISPR / Cas9 target online predictor (https: / / cctop.cos.uni-heidelberg.de:8043 / index.html). The designed sgRNA sequences were synthesized using GeneScript, cloned, and inserted into the lentiviral vector LentiCRISPRv2. The sgRNA vector, psPAX2, and pMD2G were mixed in appropriate proportions, polyetherimide (PEI) was added, and the mixture was added to HEK 293T cells and gently stirred until homogeneous. At 48 and 72 hours post-transfection, the virus-containing cell supernatant was collected, centrifuged to remove cell debris, and filtered through a 0.45 μm filter to ensure viral purity. Tumor cells were infected with filtered lentivirus for 48 hours, then the culture medium was replaced with complete medium, and the tumor cells were allowed to recover for 24 hours. Cells were then selected by adding 1 mg / mL puromycin and choosing those that had been successfully transduced. A portion of the cells was collected for PCR and Western blot experiments to verify the knockout effect of the target gene.
[0121] 2. Experimental Results
[0122] In this embodiment, to further confirm whether FUS deficiency directly promotes meningeal metastasis, FUS was knocked out in lung cancer cell lines using a CRISPR / Cas9 gene knockout system. FUS-deficient tumor cells exhibited enhanced BCSFB penetration ability. In a mouse model, FUS knockout enhanced the meningeal metastasis ability of lung cancer cells, and transplantation of FUS-deficient lung cancer cells significantly shortened the survival time of mice. In Lep cells, FUS expression levels were also significantly reduced, indicating that the absence of FUS expression promotes meningeal metastasis in lung cancer. Figure 3 ). Figure 3 This provides experimental validation of the results showing that FUS deficiency promotes leptomeningeal metastasis in lung cancer.
[0123] Figure 3 A: The mRNA expression level of lung cancer cells was detected by qPCR after FUS was knocked out; Figure 3 B: The mRNA expression level of lung cancer cells after FUS knockout was detected by Western blot. Figure 3C: Transwell assay results showed that tumor cells with FUS knocked out had stronger BCSFB penetration ability; Figure 3 D: Tumor cells with FUS knocked out or control group cells were transplanted into mice through the left ventricle, and tumor progression in mice was detected by in vivo imaging. Figure 3 E: Statistics on meningeal metastasis in tumor-bearing mice; Figure 3 F: Mouse brain tissue pathological sections showing tumor leptomeningeal metastasis, indicating that cells with FUS knockout have a higher probability of leptomeningeal metastasis. Scale bar: whole brain map 2000μm, screenshot 200μm; Figure 3 G: Survival period of tumor-bearing mice; mice transplanted with FUS knockout tumor cells have shorter survival periods. Figure 3 H: qPCR detection showed that the expression level of FUS in Lep cells was reduced compared with that in Par cells; Figure 3 I: Western blot analysis showed that the expression level of FUS was reduced in Lep cells compared with Par cells.
[0124] Example 4
[0125] Molecular characteristics of lung cancer cells metastasizing in the meninges
[0126] To further explore the molecular mechanism by which FUS deficiency promotes leptomeningeal metastasis in lung cancer, this embodiment performed transcriptome sequencing analysis on Lep-A549 / Lep-PC9 cells, A549-Par / PC9-Par cells, knockout control cells (sg-Ctl), and FUS-knockout cells (sg-FUS).
[0127] The combined analysis showed that Lep cells and sg-FUS cells exhibited high similarity in gene expression at the transcriptomic level, with significantly increased expression levels of genes related to neuroendocrine differentiation in these cells. Neuroendocrine differentiation in lung cancer is associated with its rapid malignant progression and poor prognosis. This study analyzed the disease progression of lung cancer patients with leptomeningeal metastases and found a negative correlation between patient survival time and the expression levels of neuroendocrine differentiation-related genes (NED signature: SOX2, ASCL2, MAP2, NSE, SSTR1, SSTR5) in tumor tissue. Specifically, the higher the degree of neuroendocrine differentiation in tumor tissue, the faster the disease progression after leptomeningeal metastasis, suggesting that neuroendocrine differentiation is a relevant factor in lung cancer leptomeningeal metastasis. This study further examined the expression levels of neuroendocrine differentiation-related genes in Lep cells and FUS-deficient cells. The results showed significantly increased expression of genes such as SOX2, ASCL2, MAP2, NSE, SSTR1, and SSTR5. NSE, a neuroenolase, also showed significantly increased secretion levels in Lep cells and FUS-deficient cells, indicating that tumor cells with leptomeningeal metastases possess the molecular characteristics of neuroendocrine differentiation. Figure 4 ). Figure 4 These are molecular characteristics of lung cancer cells that have metastasized to the meninges.
[0128] Figure 4 The results of Gene Set Enrichment Analysis (GSEA) showed that Lep cells and FUS knockout cells upregulated the expression of genes related to neural differentiation.
[0129] Figure 4 B: The heatmap shows that the expression levels of genes related to neural differentiation and synapse formation are increased in FUS knockout cells;
[0130] Figure 4 C: Survival analysis showed that the survival period of patients with lung cancer leptomeningeal metastases was significantly negatively correlated with the expression levels of neuroendocrine-related genes (NED signature: SOX2, ASCL2, MAP2, NSE, SSTR1, SSTR5) in the tumor.
[0131] Figure 4 D: qPCR detection showed that the expression levels of neuroendocrine differentiation-related genes such as SOX2, ASCL2, MAP2, NSE, SSTR1, and SSTR5 were significantly increased in Lep cells and FUS knockout cells.
[0132] Figure 4Western blot analysis showed that the expression levels of neuroendocrine differentiation-related genes such as SOX2, ASCL2, MAP2, NSE, SSTR1, and SSTR5 were significantly increased in Lep cells and FUS knockout cells.
[0133] Figure 4 Immunohistochemical staining showed that the expression levels of neuroendocrine differentiation-related genes such as SOX2, ASCL2, MAP2, NSE, SSTR1, and SSTR5 were significantly increased in Lep cells and FUS knockout cells.
[0134] Figure 4 ELISA assays showed that NSE secretion levels were significantly increased in Lep cells and FUS knockout cells.
[0135] Example 5
[0136] Immunohistochemical and proliferation experiments of Lep cells and FUS-deficient cells
[0137] 1. Immunohistochemistry
[0138] Mouse brain tissue was fixed in formalin, and 20 μm sections were prepared using a cryostat and embedded. After dewaxing and heat retrieval, the paraffin-embedded sections were re-exposed to antigens and then stained with H&E. Alternatively, sections were incubated overnight at 4°C with mouse anti-pan-ck (1:200, Abcam, ab86734), rabbit anti-SOX2 (1:100, Proteintech, 11064-1-AP), rabbit anti-ASCL2 (1:100, Proteintech, 21368-1-AP), rabbit anti-MAP2 (1:2500, Proteintech, 17490-1-AP), mouse anti-NSE (1:2500, Proteintech, 66150-1-Ig), rabbit anti-SSTR1 (1:200, Proteintech, 20587-1-AP), and mouse anti-SSTR5 (1:1000, Proteintech, 66772-1-Ig). Subsequently, sections were incubated with secondary antibody at 37°C for 1 hour, and slides were then stained with DAB and hematoxylin. After the coverslip has dried, it was photographed using the Tissue FAXS PlusST system (TissueGnostics).
[0139] 2. Proliferation Experiment
[0140] 1000 cells were seeded into 96-well plates to observe their proliferation. Lung cancer cells were co-cultured with human cerebrospinal fluid (CSF). CSF samples obtained from lumbar puncture of lung cancer patients were filtered through a 0.45 μm filter and mixed with basal medium (RMPI1640 medium, without fetal bovine serum) at a 1:1 ratio, which was then used as the growth medium at 37°C and a carbon dioxide concentration maintained at 5%. Cell viability was assessed at 0, 24, 48, and 72 hours post-seeding using the Cell Counting Kit-8 (CCK-8, KeyGEN) according to the manufacturer's protocol.
[0141] 3. Experimental Results
[0142] Neuroendocrine-differentiated tumor cells also exhibit morphological changes. Immunofluorescence staining analysis revealed synaptic structures in Lep cells and FUS-deficient cells, and positive expression of the neurodifferentiation-related marker MAP2, suggesting neurodifferentiation of tumor cells. Culture of tumor cells in cerebrospinal fluid showed that Lep cells and FUS-deficient cells had a stronger survival advantage in this environment. This survival advantage may be due to the neuroendocrine differentiation process that endows tumor cells with (…). Figure 5 ).
[0143] Figure 5 The results show the staining and co-culture of Lep cells and FUS-deficient cells. Figure 5 This showed that Lep cells and FUS-deficient cells had a survival advantage in cerebrospinal fluid. Figure 5 In the middle section (A), immunofluorescence staining showed that Lep cells and FUS-knockout cells exhibited neural synaptic structures and were positive for the neural differentiation-related marker MAP2. Figure 5 B: The results of co-culturing tumor cells with cerebrospinal fluid showed that Lep cells and cells with FUS knockout had a stronger survival advantage in the cerebrospinal fluid microenvironment.
[0144] Example 6
[0145] 1. Propranolol blocks neuroendocrine differentiation in lung cancer.
[0146] Propranolol (50 μM) was added to the above-mentioned cerebrospinal fluid environment culture system (RMPI1640 medium mixed with cerebrospinal fluid from lung cancer patients at a 1:1 ratio, serum-free). Cells were collected after 48 hours of culture. Changes in the transcription and expression levels of genes such as SOX2, ASCL2, MAP2, NSE, SSTR1, and SSTR5 were detected by qPCR, Western blot, and immunohistochemistry. Changes in NSE secretion levels were detected by ELISA. Cell staining levels of SOX2, ASCL2, MAP2, and NSE, as well as synapse formation, were detected by immunofluorescence.
[0147] 2. Propranolol inhibits lung cancer leptomeningeal metastasis in a mouse model.
[0148] A mouse model of lung cancer with leptomeningeal metastasis was established via intraventricular injection. Mice were administered 20 mg / kg propranolol via intraventricular injection every 3 days. Mouse weight and health status were observed. Tumor burden in the brain was monitored using bioluminescence imaging (BLI), and the endpoint of the survival curve was recorded. Brain tissue from deceased mice was collected for pathological analysis to determine the extent of leptomeningeal metastasis.
[0149] 3. Experimental Results
[0150] Propranolol inhibits tumor cell proliferation, migration, invasion, and angiogenesis, and improves the tumor microenvironment. It has been studied for preoperative treatment of various cancers, including breast cancer, melanoma, prostate cancer, liver cancer, gastric cancer, and thyroid cancer. Propranolol slows tumor growth by inhibiting neuroendocrine differentiation in prostate cancer. This invention treats Lep cells and FUS-deficient cells in the cerebrospinal fluid environment with propranolol (50 μM). The results showed a decrease in the expression levels of genes related to neuroendocrine differentiation, suggesting that propranolol blocks the neuroendocrine differentiation of lung cancer cells. Treatment with propranolol (50 μM) significantly reduced the survival advantage of Lep cells and FUS-deficient cells in the cerebrospinal fluid microenvironment. A mouse model of lung cancer leptomeningeal metastasis was established by intraventricular injection. Mice were treated with 20 mg / kg propranolol via intraventricular injection every 3 days, while mice in the non-treatment group received an equal volume of DMSO via intraventricular injection. Two groups of mice were observed daily for body weight and health status. Tumor burden was monitored using bioluminescence imaging (BLI). Once mice exhibited obvious symptoms such as central nervous system tumors, drastic weight loss, and gait instability, they were euthanized with CO2, and this was recorded as the endpoint of the individual's survival curve. Results showed that propranolol treatment inhibited tumor growth in the meninges or cerebrospinal fluid and prolonged the survival of tumor-bearing mice. Figure 6 and Figure 7 ).
[0151] Figure 6 The results of the experiment on propranolol inhibiting meningeal metastasis showed that propranolol inhibited meningeal metastasis and prolonged the survival time of tumor-bearing mice.
[0152] Figure 6 In the first case, Lep cells and FUS-knockout cells in the cerebrospinal fluid environment were treated with propranolol (50 μM). Western blot analysis showed that the expression levels of genes related to neuroendocrine differentiation decreased.
[0153] Figure 6 B: Results of co-culturing tumor cells with cerebrospinal fluid. The results showed that Lep cells treated with propranolol had a survival advantage over FUS-knockout cells in the cerebrospinal fluid microenvironment.
[0154] Figure 6 C: Schematic diagram of the in vivo verification of propranolol's inhibition of meningeal metastasis: A mouse model of lung cancer meningeal metastasis was established by intraventricular injection. Mice were treated with 20 mg / kg propranolol by intraventricular injection every 3 days, while mice in the non-treatment group were injected with an equal amount of solvent DMSO into the intraventricular.
[0155] Figure 6 In the middle D, the tumor progression in mice was detected by in vivo imaging. Propranolol treatment effectively inhibited tumor growth in the cerebrospinal fluid; Veh: DMSO; Pro: propranolol.
[0156] Figure 7 The study showed that propranolol treatment prolonged the survival rate of tumor-bearing mice.
[0157] In summary, this invention constructed a mouse model of lung cancer leptomeningeal metastasis, obtained cells with high metastatic potential, and identified the neuroendocrine differentiation level of the leptomeningeal metastatic cells. Changes in the transcriptional and expression levels of genes such as SOX2, ASCL2, MAP2, NSE, SSTR1, and SSTR5 were detected by qPCR, Western blot, and immunohistochemistry; changes in NSE secretion levels were detected by ELISA; and the staining levels of SOX2, ASCL2, MAP2, and NSE, as well as synapse formation, were detected by immunofluorescence. The proliferation capacity of leptomeningeal metastatic cells in the cerebrospinal fluid microenvironment was also examined. These experiments revealed that neuroendocrine differentiation is a key regulatory factor in lung cancer leptomeningeal metastasis. Based on this, propranolol was used to block the neuroendocrine differentiation of lung cancer cells, thereby inhibiting lung cancer leptomeningeal metastasis. The experimental results of this invention indicate that inhibiting the neuroendocrine differentiation of lung cancer cells with propranolol can treat lung cancer leptomeningeal metastasis, ultimately improving or treating lung cancer.
[0158] The applicant declares that the above description is only a specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Those skilled in the art should understand that any changes or substitutions that can be easily conceived by those skilled in the art within the technical scope disclosed in the present invention fall within the protection and disclosure scope of the present invention.
Claims
1. Application of substances that block neuroendocrine differentiation in the preparation of drugs that inhibit meningeal metastasis of lung cancer cells.
2. The use of propranolol or its pharmaceutically acceptable salts in the preparation of drugs for inhibiting meningeal metastasis in lung cancer.
3. The application according to claim 2, characterized in that, The drug blocks the neuroendocrine differentiation of lung cancer cells; Preferably, the drug inhibits the formation of neural synaptic structures.
4. The application according to claim 2 or 3, characterized in that, The drug reduces the survival ability of lung cancer cells in the cerebrospinal fluid environment.
5. The use of propranolol or a pharmaceutically acceptable salt thereof in the preparation of a neuroendocrine differentiation inhibitor for lung cancer cells.
6. A method for constructing a mouse model of lung cancer leptospirosis, characterized in that, The method includes: injecting lung cancer cells with the FUS gene knocked out into the left ventricle of mice to obtain a mouse model of lung cancer with meningeal metastasis.
7. The method for constructing a mouse model of lung cancer leptospirosis according to claim 6, characterized in that, The step of knocking out the FUS gene includes: infecting lung cancer cells with lentivirus containing sgRNA and Cas9 that target the FUS gene, and then screening to obtain lung cancer cells with the FUS gene knocked out. Preferably, the nucleotide sequence targeted by the sgRNA includes those shown in SEQ ID NO:1 and SEQ ID NO:
2.
8. The use of the mouse model of lung cancer leptomeningeal metastasis as described in claim 6 or 7 in evaluating the therapeutic effect of drugs that inhibit lung cancer leptomeningeal metastasis.
9. Application of reagents for detecting the secretion level of neuroenolase (NSE) in the preparation of diagnostic products for leptomeningeal metastasis of lung cancer.
10. Application of neuroenolase NSE as a detection and / or therapeutic target in the preparation of diagnostic and / or inhibitory products for lung cancer leptomeningeal metastasis.
Citation Information
Patent Citations
A method for establishing an immunodeficient mouse model
CN103409468B
